Amgen paying Arrowhead for traits to develop cardiovascular drugs
Amgen will license two traits from a Pasadena pharmaceutical company to develop cardiovascular drugs under a partnership announced Sept. 29. Under the agreement, Thousand Oaks-based Amgen will pay Arrowhead Pharmaceuticals $35 million up front, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in Read More →
Editorial: Ebola eradication effort turns to region’s experts
In the case of Direct Relief and Amgen, their efforts to bring the Ebola outbreak under control may be more than noteworthy. They may help make history.
Amgen reports positive trial results for high-cholesterol treatment
The portion of Amgen’s Phase 3 trial of evolocumab that evaluated patients with high cholesterol who cannot tolerate statins has met goals related to percent reduction of low-density lipoprotein cholesterol.
Editorial: FDA rules aim to curb prescription drug abuse
The Food and Drug Administration has come up with new rules aimed at curbing an epidemic of pain pill addiction.
Ventura County sheriff takes aim at rougue doctors, pharmacists
Suddenly, the buzz among my peers over dinner and drinks has turned to the television show “Breaking Bad.” Whether you’re a fan of the show on cable, on DVD or perhaps a casual channel surfer like me, there is a morbid fascination with the tale of a teacher-turned-meth-mogul and the characters around him. Which brings Read More →
Amgen gets sought-after FDA approval
The Food and Drug Administration has approved the use of Amgen’s bone drug denosumab in patients with certain types of cancer, Amgen announced Nov. 18.
